https://ir.lixte.com/ https://ir.lixte.com/news-events https://ir.lixte.com/news-events/press-releases https://ir.lixte.com/news-events/ir-calendar https://ir.lixte.com/news-events/email-alerts https://ir.lixte.com/company-information https://ir.lixte.com/company-information/management-team https://ir.lixte.com/company-information/presentations https://ir.lixte.com/company-information/contacts https://ir.lixte.com/company-information/faq https://ir.lixte.com/financial-information https://ir.lixte.com/financial-information/financial-results https://ir.lixte.com/financial-information/income-statement https://ir.lixte.com/financial-information/balance-sheet https://ir.lixte.com/financial-information/cash-flow https://ir.lixte.com/stock-data/quote-chart https://ir.lixte.com/stock-data/historical-data https://ir.lixte.com/sec-filings https://ir.lixte.com/sec-filings/all-sec-filings https://ir.lixte.com/sec-filings/annual-reports https://ir.lixte.com/sec-filings/quarterly-reports https://ir.lixte.com/sec-filings/section-16-filings https://ir.lixte.com/corporate-governance https://ir.lixte.com/corporate-governance/board-of-directors https://ir.lixte.com/corporate-governance/board-committees https://ir.lixte.com/corporate-governance/governance-documents https://ir.lixte.com/corporate-governance/board-diversity-matrix https://ir.lixte.com/news-events/press-releases/detail/146/lixte-biotechnology-files-2025-annual-report-on-form-10k-provides-operational-highlights-of-transformative-year https://ir.lixte.com/news-events/press-releases/detail/145/lixte-biotechnology-appoints-sidney-braun-as-ceo-of-its-liora-technologies-europe-ltd-subsidiary https://ir.lixte.com/news-events/press-releases/detail/144/de-la-soul-led-good-health-summit-launches-february-19-at-morehouse-college https://ir.lixte.com/news-events/press-releases/detail/143/lixte-biotechnology-attending-the-dealflow-discovery-conference-january-28-29 https://ir.lixte.com/news-events/press-releases/detail/142/lixte-and-its-collaborators-expand-clear-cell-ovarian-cancer-trial https://ir.lixte.com/news-events/press-releases/detail/141/lixte-biotechnology-holdings-inc-announces-4-3-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules https://ir.lixte.com/news-events/press-releases/detail/140/lixte-biotechnology-acquires-liora-technologies-proprietary-proton-therapy-platform-for-cancer-treatment https://ir.lixte.com/news-events/press-releases/detail/139/lixte-biotechnology-holdings-to-present-at-the-spartan-capital-investor-conference-2025-november-3 https://ir.lixte.com/news-events/press-releases/detail/138/lixte-biotechnology-holdings-highlights-q4-2025-priorities-including-ongoing-advancement-of-lead-candidate-lb-100-strategic-oncology-business-development-and-acquisition-plans https://ir.lixte.com/news-events/press-releases/detail/137/lixte-biotechnology-holdings-makes-2-6-million-initial-purchase-of-digital-currency-to-diversify-treasury-and-for-potential-acquisitions https://ir.lixte.com/news-events/press-releases/detail/136/lixte-biotechnology-holdings-appoints-two-new-board-members-and-new-chief-financial-officer https://ir.lixte.com/news-events/press-releases/detail/133/lixte-biotechnology-holdings-provides-corporate-update https://ir.lixte.com/news-events/press-releases/detail/129/lixte-biotechnology-holdings-updates-corporate-treasury-policy-to-include-cryptocurrency https://ir.lixte.com/news-events/press-releases/detail/128/lixte-biotechnology-holdings-regains-compliance-with-nasdaqs-continued-listing-requirements https://ir.lixte.com/news-events/press-releases/detail/127/new-clinical-findings-published-in-scientific-journal-nature-validate-lixtes-ongoing-ovarian-and-colorectal-cancer-trials https://ir.lixte.com/news-events/press-releases/detail/126/lixte-biotechnology-holdings-inc-announces-the-closing-of-1-5-million-registered-direct-offering https://ir.lixte.com/news-events/press-releases/detail/125/lixte-biotechnology-holdings-inc-announces-the-closing-of-5-0-million-private-placement-priced-at-the-market https://ir.lixte.com/news-events/press-releases/detail/124/lixte-biotechnology-holdings-inc-announces-5-0-million-private-placement-priced-at-the-market https://ir.lixte.com/news-events/press-releases/detail/123/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100 https://ir.lixte.com/news-events/press-releases/detail/122/lixte-biotechnology-provides-update-on-progress-with-proprietary-compound-lb-100-to-treat-ovarian-and-colorectal-cancer https://ir.lixte.com/news-events/press-releases/detail/121/new-findings-show-how-lixtes-lead-clinical-compoundlb-100-is-metabolized-to-its-active-form https://ir.lixte.com/news-events/press-releases/detail/120/lixte-adds-northwestern-universitys-lurie-cancer-center-as-second-site-in-ongoing-clinical-trial-for-ovarian-clear-cell-cancer https://ir.lixte.com/news-events/press-releases/detail/119/lixte-biotechnology-announces-closing-of-1-05-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules https://ir.lixte.com/news-events/press-releases/detail/118/lixte-biotechnology-announces-1-05-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules https://ir.lixte.com/news-events/press-releases/detail/117/lixte-biotechnology-submits-request-for-withdrawal-of-form-s-1-registration-statement https://ir.lixte.com/news-events/press-releases/detail/116/lixte-receives-u-s-patent-issue-notification-for-immune-oncology https://ir.lixte.com/news-events/press-releases/detail/115/first-patient-dosed-with-lixtes-lb-100-in-new-clinical-trial-to-treat-colorectal-cancer-collaborating-with-nki-supported-by-major-pharma-company https://ir.lixte.com/news-events/press-releases/detail/114/lixte-biotechnology-provides-update-on-recent-activities-and-developments https://ir.lixte.com/news-events/press-releases/detail/113/lixte-biotechnology-holdings-to-present-at-two-investor-conferences https://ir.lixte.com/news-events/press-releases/detail/112/lixte-biotechnology-holdings-inc-to-present-at-august-20th-virtual-investor-summit-microcap-event https://ir.lixte.com/news-events/press-releases/detail/111/lixte-biotechnology-holdings-announces-collaboration-on-a-new-colon-cancer-clinical-trial https://ir.lixte.com/news-events/press-releases/detail/109/scientific-journal-reports-findings-that-show-lixtes-lead-clinical-compoundlb-100-increases-recognition-of-colon-cancer-cells-by-the-immune-system https://ir.lixte.com/news-events/press-releases/detail/108/lixte-biotechnology-holdings-names-distinguished-oncologist-jan-schellens-as-chief-medical-officer https://ir.lixte.com/news-events/press-releases/detail/107/lixte-biotechnology-holdings-provides-update-on-recent-activities https://ir.lixte.com/news-events/press-releases/detail/106/lixte-biotechnology-co-sponsoring-international-scientific-conference-on-therapeutic-over-activation-in-cancer https://ir.lixte.com/news-events/press-releases/detail/105/new-scientific-publication-shows-lb-100-lixtes-lead-clinical-compound-can-force-cancer-cells-to-give-up-their-cancer-causing-properties https://ir.lixte.com/news-events/press-releases/detail/104/lixte-provides-update-on-progress-with-lb-100-as-a-pp2a-inhibitor-to-enhance-chemotherapy-and-immunotherapy-cancer-treatments https://ir.lixte.com/news-events/press-releases/detail/103/professor-ren-bernards-to-present-new-pre-clinical-data-on-lixtes-lb-100-at-joint-conference-of-european-and-american-associations-for-cancer-research https://ir.lixte.com/news-events/press-releases/detail/102/lixte-biotechnology-enters-into-exclusive-immune-oncology-patent-license-agreement-with-ninds-and-nci https://ir.lixte.com/news-events/press-releases/detail/101/first-patient-dosed-with-lixtes-lb-100-and-gsks-immunotherapy-dostarlimab-gxly-in-ovarian-clear-cell-carcinoma-trial https://ir.lixte.com/news-events/press-releases/detail/100/lixte-biotechnology-provides-update-on-clinical-progress-and-expanding-collaborations https://ir.lixte.com/news-events/press-releases/detail/99/lixte-netherlands-cancer-institute-and-oncode-institute-to-expand-collaboration https://ir.lixte.com/news-events/press-releases/detail/98/lixte-biotechnology-holdings-announces-the-passing-of-its-founder-john-s-kovach https://ir.lixte.com/news-events/press-releases/detail/97/lixte-appoints-bas-van-der-baan-as-president-and-chief-executive-officer https://ir.lixte.com/news-events/press-releases/detail/96/lixte-biotechnology-announces-a-supported-collaborative-trial-to-study-lixtes-first-in-class-pp2a-inhibitor-lb-100-plus-gsks-immunotherapy-dostarlimab-in-clear-cell-ovarian-cancer https://ir.lixte.com/news-events/press-releases/detail/95/lixte-biotechnology-announces-closing-of-3-5-million-registered-direct-offering-and-concurrent-private-placement-priced-at-the-market-under-nasdaq-rules https://ir.lixte.com/news-events/press-releases/detail/94/lixte-biotechnology-announces-pricing-of-3-5-million-registered-direct-offering-and-concurrent-private-placement-priced-at-the-market-under-nasdaq-rules https://ir.lixte.com/news-events/press-releases/detail/93/preclinical-results-of-lixte-biotechnologys-collaboration-with-netherlands-cancer-institute-reveal-novel-mechanism-by-which-lixtes-lead-clinical-compound-lb-100-enhances-effectiveness-of-immunotherapy-and-chemotherapy https://ir.lixte.com/news-events/press-releases/detail/92/lixte-biotechnology-holdings-inc-regains-compliance-with-nasdaq-continued-listing-requirements https://ir.lixte.com/news-events/press-releases/detail/91/lixte-biotechnology-and-the-spanish-sarcoma-group-enroll-first-patient-in-a-phase-1b2-randomized-trial-of-doxorubicin---lixtes-lead-anti-cancer-compound-lb-100-in-advanced-soft-tissue-sarcomas https://ir.lixte.com/news-events/press-releases/detail/90/lixte-biotechnology-holdings-inc-announces-1-for-10-reverse-stock-split-of-its-common-stock-effective-on-pre-market-opening-on-june-5-2023 https://ir.lixte.com/news-events/press-releases/detail/89/recently-published-independent-research-reveals-new-mechanisms-by-which-lixte-biotechnologys-lead-clinical-compound-lb-100-increases-effectiveness-of-cancer-immunotherapy https://ir.lixte.com/news-events/press-releases/detail/88/lixte-biotechnology-reports-first-spanish-site-activated-to-begin-accrual-of-patients-for-a-phase-1b2-clinical-trial-of-lixtes-lead-anti-cancer-compound-lb-100-added-to-doxorubicin-as-first-line-treatment-of-advanced-soft-tissue-sarcoma https://ir.lixte.com/news-events/press-releases/detail/87/lixte-biotechnology-announces-sarah-cannon-research-institute-joins-city-of-hopes-ongoing-phase-1b-clinical-trial-in-evaluating-lixtes-lead-anti-cancer-compound-lb-100-in-small-cell-lung-cancer https://ir.lixte.com/news-events/press-releases/detail/86/lixte-biotechnology-holdings-reports-newly-published-independent-pre-clinical-research https://ir.lixte.com/news-events/press-releases/detail/85/lixte-biotechnology-holdings-inc-reports-that-its-lead-clinical-compound-lb-100-can-kill-cancer-cells-through-hyper-stimulation-of-cell-proliferation-signals-in-pre-clinical-models https://ir.lixte.com/news-events/press-releases/detail/84/lixte-biotechnology-holdings-to-present-at-planet-microcap-showcase-virtual-2022-investor-conference https://ir.lixte.com/news-events/press-releases/detail/83/lixte-biotechnology-announces-approval-of-a-phase-1b2-randomized-trial-of-doxorubicin--lb-100-in-advanced-soft-tissue-sarcomas-to-be-conducted-by-the-spanish-sarcoma-group https://ir.lixte.com/news-events/press-releases/detail/82/lixte-biotechnology-announces-appointment-of-bas-van-der-baan-internationally-recognized-biotech-business-development-executive-to-its-board-of-directors https://ir.lixte.com/news-events/press-releases/detail/81/lixte-biotechnology-announces-appointment-of-professor-ren-bernards-to-its-board-of-directors https://ir.lixte.com/news-events/press-releases/detail/80/lixte-biotechnology-announces-the-closing-of-5-8-million-registered-direct-offering-priced-at-the-market https://ir.lixte.com/news-events/press-releases/detail/79/lixte-biotechnology-announces-5-8-million-registered-direct-offering-priced-at-the-market https://ir.lixte.com/news-events/press-releases/detail/78/lixte-biotechnology-announces-preclinical-results-of-its-collaboration-with-the-netherlands-cancer-institute-revealing-striking-anti-cancer-activity-of-lb-100-in-novel-drug-combinations https://ir.lixte.com/news-events/press-releases/detail/77/inactivating-mutations-in-scaffold-component-of-pp2a-the-target-enzyme-of-lixte-biotechnologys-clinical-compound-lb-100-are-associated-with-exceptionally-long-survival-of-patients-with-ovarian-clear-cell-cancer-treated-with-immunotherapy https://ir.lixte.com/news-events/press-releases/detail/76/lixte-biotechnology-holdings-inc-to-present-at-medinvest-pharmaceutical-and-biotechnology-investor-conference https://ir.lixte.com/news-events/press-releases/detail/75/lixte-biotechnology-announces-filing-of-first-patent-application-resulting-from-collaboration-with-the-netherlands-cancer-institute-and-the-oncode-institute-to-identify-the-most-promising-drug-combinations-for-lead-clinical-compound-lb-100 https://ir.lixte.com/news-events/press-releases/detail/74/lixte-biotechnologys-lb-100-reported-to-convert-immunologically-unresponsive-cold-tumors-to-immunologically-responsive-hot-tumors https://ir.lixte.com/news-events/press-releases/detail/73/lixte-biotechnology-holdings-inc-announces-that-enrollment-has-resumed-in-national-cancer-institutes-trial-to-determine-ability-of-lixte-compound-lb-100-to-enter-recurrent-malignant-brain-tumors https://ir.lixte.com/news-events/press-releases/detail/72/lixte-biotechnology-to-discuss-its-collaboration-with-leading-european-cancer-centers-at-the-benzinga-global-small-cap-conference-on-october-28 https://ir.lixte.com/news-events/press-releases/detail/71/lixte-biotechnology-announces-collaboration-with-netherlands-cancer-institute-amsterdam-and-oncode-institute-utrecht-to-identify-the-most-promising-drug-combinations-for-its-lead-clinical-compound-lb-100-for-cancer-treatment https://ir.lixte.com/news-events/press-releases/detail/70/lixte-biotechnologys-lb-100-shown-in-animal-modelsto-significantly-reduce-behavioral-sensitizationan-important-feature-of-methamphetamine-addiction https://ir.lixte.com/news-events/press-releases/detail/69/lixte-biotechnologys-lb-100-elicits-anti--tumor-activity-in-small-lung-cancer-models-by-unique-mechanisms-in-an-important-pre-clinical-study https://ir.lixte.com/news-events/press-releases/detail/68/lixte-biotechnology-comments-on-report-that-its-pp2a-inhibitor-lb-100-combined-with-another-investigational-agent-stimulates-bone-growth-in-models-of-dwarfism https://ir.lixte.com/news-events/press-releases/detail/67/lixte-biotechnology-comments-on-outside-research-citing-lb-100s-pp2a-inhibition-as-a-potential-therapeutic-strategy-for-triple-negative-breast-cancer https://ir.lixte.com/news-events/press-releases/detail/66/lixte-biotechnology-to-present-its-drug-development-pipeline-for-cancer-treatment-at-the-moneyshow-virtual-expo-on-july-14-2021 https://ir.lixte.com/news-events/press-releases/detail/65/lixte-biotechnology-and-city-of-hope-enroll-first-patient-in-phase-1b-trial-of-lead-compound-lb-100-for-treatment-of-small-cell-lung-cancer https://ir.lixte.com/news-events/press-releases/detail/64/lixte-biotechnology-holdings-inc-announces-the-appointment-of-regina-brown-to-its-board-of-directors https://ir.lixte.com/news-events/press-releases/detail/63/lixte-biotechnology-to-present-key-advantages-of-novel-cancer-drug-candidate-lb-100-at-the-sidoti-virtual-microcap-conference-on-may-20 https://ir.lixte.com/news-events/press-releases/detail/62/lixte-biotechnology-to-discuss-pipeline-of-clinical-investigations-for-four-cancer-targets-at-the-benzinga-global-small-cap-conference-being-held-may-13-14 https://ir.lixte.com/news-events/press-releases/detail/61/lixte-biotechnology-holdings-inc-announces-the-appointment-of-gil-n-schwartzberg-to-its-board-of-directors https://ir.lixte.com/news-events/press-releases/detail/60/lixte-biotechnology-to-present-its-novel-product-candidate-for-targeted-cancer-therapy-at-the-benzinga-biotech-small-cap-conference-on-march-24 https://ir.lixte.com/news-events/press-releases/detail/59/lixte-biotechnology-to-showcase-its-anti-cancer-therapy-enhancer-lb-100-at-the-virtual-33rd-annual-roth-capital-conference https://ir.lixte.com/news-events/press-releases/detail/58/lixte-biotechnology-announces-the-closing-of-4-19-million-registered-direct-offering https://ir.lixte.com/news-events/press-releases/detail/57/lixte-biotechnology-announces-4-19-million-registered-direct-offering https://ir.lixte.com/news-events/press-releases/detail/56/lixte-biotechnology-to-present-its-anti-cancer-therapy-enhancer-lb-100-at-the-virtual-h-c-wainwright-global-life-sciences-conference https://ir.lixte.com/news-events/press-releases/detail/55/lixte-biotechnology-and-city-of-hope-to-initiate-phase-1b-clinical-trial-of-lixtes-lead-compound-lb-100-to-treat-small-cell-lung-cancer https://ir.lixte.com/news-events/press-releases/detail/5/lixte-biotechnology-holdings-inc-announces-closing-of-public-offering-and-uplisting-to-nasdaq https://ir.lixte.com/news-events/press-releases/detail/6/lixte-biotechnology-holdings-inc-announces-pricing-of-5700000-public-offering-uplisting-to-nasdaq-capital-market-and-reverse-stock-split https://ir.lixte.com/news-events/press-releases/detail/7/the-foundation-for-angelman-syndrome-therapeutics-fast-and-lixte-biotechnology-collaborate-to-support-the-preclinical-study-of-lixtes-protein-phosphatase-2a-inhibitor-lb-100-as-a-possible-treatment-for-angelman-syndrome https://ir.lixte.com/news-events/press-releases/detail/8/lixte-biotechnology-holdings-inc-announces-the-appointment-of-internationally-recognized-clinical-cancer-investigator-james-s-miser-md-as-chief-medical-officer https://ir.lixte.com/news-events/press-releases/detail/9/lixte-biotechnologys-pp2a-inhibitor-lb-100-enhances-the-effectiveness-of-pd1-immune-blockade-in-mouse-models-of-glioblastoma-brain-tumors https://ir.lixte.com/news-events/press-releases/detail/10/first-two-patients-enrolled-in-national-cancer-institute-trial-of-the-ability-of-lixte-biotechnologys-lb-100-to-enter-recurrent-malignant-brain-tumors https://ir.lixte.com/news-events/press-releases/detail/11/the-spanish-sarcoma-group-will-lead-a-european-consortium-to-evaluate-the-ability-of-lixte-biotechnology-holdings-lb-100-to-improve-first-line-therapy-for-advanced-soft-tissue-sarcomas https://ir.lixte.com/news-events/press-releases/detail/12/first-patient-enrolled-in-phase-1b2-trial-of-lixte-biotechnologys-lb-100-in-low-or-intermediate-1-risk-myelodysplastic-syndrome https://ir.lixte.com/news-events/press-releases/detail/13/lixte-biotechnologys-pp2a-inhibitor-lb-100-improves-brain-function-and-motor-impairment-in-a-mouse-model-of-angelman-syndrome-a-rare-human-neurodevelopmental-disorder https://ir.lixte.com/news-events/press-releases/detail/14/lixte-biotechnologys-lb-100-to-be-evaluated-by-the-national-cancer-institute-in-a-clinical-study-of-lb-100s-ability-to-enter-recurrent-glioblastoma-multiforme-brain-tumors https://ir.lixte.com/news-events/press-releases/detail/15/fda-approves-lixte-biotechnologys-ind-to-conduct-a-phase-1b2-trial-of-lb-100-in-patients-with-myelodysplastic-syndrome-at-moffitt-cancer-center https://ir.lixte.com/news-events/press-releases/detail/16/lixte-biotechnology-files-an-ind-with-the-fda-to-conduct-a-phase-1b2-trial-of-lb-100-in-patients-with-myelodysplastic-syndrome-at-moffitt-cancer-center https://ir.lixte.com/news-events/press-releases/detail/17/lixte-biotechnology-announces-a-clinical-trial-agreement-with-moffitt-cancer-center-to-initiate-phase-1b2-trial-evaluating-the-safety-and-efficacy-of-lb-100-in-treatment-of-patients-with-low-or-intermediate-1-risk-myelodysplastic-syndrome https://ir.lixte.com/news-events/press-releases/detail/18/yun-yen-md-phd-and-winson-sze-chun-ho-md-join-lixte-biotechnologys-board-of-directors https://ir.lixte.com/news-events/press-releases/detail/19/lb-100-and-lb-102-lixte-biotechnologys-protein-phosphatase-2a-inhibitors-sensitize-bcr-abl-leukemia-stem-cells-to-targeted-therapy-with-tyrosine-kinase-inhibitors https://ir.lixte.com/news-events/press-releases/detail/20/lixte-biotechnologys-protein-phosphatase-2a-inhibitor-lb-100-reported-to-be-a-potentiator-of-immunotherapy-in-an-animal-model https://ir.lixte.com/news-events/press-releases/detail/21/late-breaking-abstract-on-lb-100-lixte-biotechnologys-protein-phosphatase-2a-inhibitor-in-combination-with-a-pd-1-inhibitor-in-an-animal-model-to-be-presented-at-the-aacr-annual-meeting https://ir.lixte.com/news-events/press-releases/detail/22/first-in-human-assessment-of-lb-100-lixte-biotechnologys-protein-phosphatase-2a-inhibitor-published-in-clinical-cancer-research https://ir.lixte.com/news-events/press-releases/detail/23/dr-stephen-forman-joins-lixte-biotechnologys-board-of-directors https://ir.lixte.com/news-events/press-releases/detail/24/lixte-biotechnology-holdings-inc-s-lead-compound-lb-100-reported-to-rapidly-improve-symptoms-in-a-rodent-model-of-depression https://ir.lixte.com/news-events/press-releases/detail/25/lixte-completes-private-placement-of-convertible-preferred-stock https://ir.lixte.com/news-events/press-releases/detail/26/lixte-biotechnology-holdings-inc-announces-exclusive-licensing-of-their-lead-anti-cancer-compound-lb-100-for-potential-treatment-of-hepatocellular-carcinoma-in-asia-to-taipei-medical-university https://ir.lixte.com/news-events/press-releases/detail/27/lixte-biotechnology-holdings-inc-announces-that-its-novel-protein-phosphatase-2a-inhibitor-is-associated-with-stabilization-of-several-types-of-cancer-without-dose-limiting-toxicity https://ir.lixte.com/news-events/press-releases/detail/28/lixte-biotechnology-holdings-inc-engages-biopharmaworks-llc-to-enhance-development-of-its-pipeline-of-novel-compounds https://ir.lixte.com/news-events/press-releases/detail/29/lixte-completes-private-placement-of-convertible-preferred-stock https://ir.lixte.com/news-events/press-releases/detail/30/lixte-biotechnologys-lead-compound-reported-to-be-active-against-hematologic-cancers-in-pre-clinical-studies https://ir.lixte.com/news-events/press-releases/detail/31/lixte-biotechnology-holdings-announces-expansion-of-clinical-sites-for-its-phase-i-trial-of-its-lead-anti-cancer-compound-lb-100 https://ir.lixte.com/news-events/press-releases/detail/32/lixtes-lb-100-selected-as-one-of-informa-and-kantar-healths-2014-top-10-most-interesting-oncology-projects-to-watch https://ir.lixte.com/news-events/press-releases/detail/33/lixtes-lead-compound-lb-100-reported-to-enhance-chemotherapy-effectiveness-in-animal-models-of-liver-cancer https://ir.lixte.com/news-events/press-releases/detail/34/dr-daniel-von-hoff-joins-lixte-biotechnologys-scientific-advisory-board https://ir.lixte.com/news-events/press-releases/detail/35/lixte-biotechnology-announces-initiation-of-a-phase-i-trial-of-its-lead-anti-cancer-compound-lb-100 https://ir.lixte.com/news-events/press-releases/detail/36/lixte-biotechnology-holdings-announces-new-appointment-to-board-of-directors https://ir.lixte.com/news-events/press-releases/detail/37/lixte-biotechnology-holdings-announces-increased-funding-and-fda-allowance-to-conduct-a-phase-i-trial-of-its-lead-anti-cancer-compound-lb-100 https://ir.lixte.com/news-events/press-releases/detail/38/lixte-biotechnology-holdings-announces-submission-of-an-ind-to-the-fda-for-approval-of-a-clinical-trial-of-lb-100-a-first-in-class-anti-cancer-compound https://ir.lixte.com/news-events/press-releases/detail/39/lixte-biotechnology-receives-us-patent-for-its-proprietary-histone-deacetylase-inhibitor https://ir.lixte.com/news-events/press-releases/detail/40/lixte-biotechnology-holdings-announces-issuance-of-u-s-patent-for-agents-for-the-treatment-of-neurodegenerative-diseases https://ir.lixte.com/news-events/press-releases/detail/41/lixte-biotechnology-holdings-compound-lb-205-reported-to-have-therapeutic-potential-for-gaucher-disease https://ir.lixte.com/news-events/press-releases/detail/42/lixte-biotechnology-holdings-announces-issuance-of-u-s-patent-for-lead-anti-cancer-compound https://ir.lixte.com/news-events/press-releases/detail/43/lixte-biotechnology-holdings-announces-new-appointment-to-board-of-directors https://ir.lixte.com/news-events/press-releases/detail/44/lixte-biotechnology-holdings-inc-awarded-grant-under-qualifying-therapeutic-discovery-project-from-the-u-s-government https://ir.lixte.com/news-events/press-releases/detail/45/lixte-biotechnology-holdings-inc-announces-the-approval-of-a-collaboration-with-the-national-cancer-institute-for-clinical-evaluation-of-its-lead-anti-cancer-compound-lb-100 https://ir.lixte.com/news-events/press-releases/detail/46/lixte-biotechnology-holdings-lead-compound-lb-1-2-enhances-the-effectiveness-of-standard-cancer-chemotherapy-in-animal-models https://ir.lixte.com/news-events/press-releases/detail/47/lixte-biotechnology-holdings-announces-new-appointment-to-board-of-directors https://ir.lixte.com/news-events/press-releases/detail/48/lixte-biotechnology-holdings-announces-filing-of-a-new-patent-application-for-cancer-therapy-based-on-targeting-a-biomarker-by-novel-investigational-agents https://ir.lixte.com/news-events/press-releases/detail/49/lixte-biotechnology-holdings-announces-extension-of-its-cooperative-research-and-development-agreement-with-the-national-institute-of-neurological-disorders-and-stroke-national-institutes-of-health-for-development-of-anti-brain-cancer-drugs https://ir.lixte.com/news-events/press-releases/detail/50/lixte-biotechnology-holdings-inc-announces-further-developments-regarding-the-anti-cancer-activity-of-its-patent-pending-proprietary-compounds https://ir.lixte.com/news-events/press-releases/detail/51/lixte-biotechnology-holdings-inc-announces-completion-of-private-placement https://ir.lixte.com/news-events/press-releases/detail/52/lixte-biotechnology-holdings-announces-new-appointment-to-board-of-directors https://ir.lixte.com/news-events/press-releases/detail/53/lixte-biotechnology-holdings-inc-announces-the-initial-trading-of-its-common-stock-under-the-symbol-lixt https://ir.lixte.com/news-events/press-releases/detail/54/lixte-biotechnology-to-obtain-high-quality-tissue-and-blood-samples-from-german-university https://ir.lixte.com/privacy-policy https://ir.lixte.com/disclaimer https://ir.lixte.com/sitemap